Immunodetection of IR/IGF1R (brown cells) in a high-grade glioma tumor after targeted therapy indicating insulin pathway activity in tumor cells surviving targeted therapy. (PRNewsfoto/Norris Cotton Cancer Center, Da)

LEBANON, NH Dartmouth scientists found a therapeutic approach that should prevent the development of resistance to anti-tumor drugs in gliomas. Glioblastoma multiforme is one of the most common and deadly brain tumors. Despite the initial responsiveness to state-of-the-art therapies, tumors nearly always become resistant and eventually recur.  A group of researchers at Dartmouth’s Norris Cotton Cancer Center, led by Damian A. Almiron Bonnin, MD-Ph.D., is devising strategies to prevent brain tumors from becoming resistant to anti-tumor drug treatment.

Brain tumors are responsible for 25 percent of all cancer-related deaths in children and young adults. They quickly develop chemotherapeutic resistance, so current specific treatments are largely ineffective.

Almiron Bonnin’s study will lead to a better understanding of cancer mechanisms (drug resistance) that will hopefully translate into improved clinical therapies for the treatment of high-grade gliomas.